RIDO Hedge Funds Investment TV

.

Friday, May 09, 2014

Hedge Fund Returns Are Falling Because Hedge Fund Returns Used To Be Just Great

Tim Worstall, Contributor
Posted on 5/09/2014 @ 10:58AM
Article from http://www.forbes.com/


Dam McCrum over at FT Alphaville has a look at why the top hedge fund managers are making so much darn money. I don’t disagree with anything he says I just want to pick up on a point and expand it. For we can explain some of what has been happening just with some pure Adam Smith from a couple of centuries ago. what is being said here about new and small hedge funds also rather applies to the entire industry:
Small and young hedge funds are nimble, their managers are focused, and they can concentrate their capital in a small number of good ideas without moving prices or attracting attention. One study by Barclays found that funds under two year’s old, and managing less than $100m typically make better investment returns than their larger older peers.
They’re also more likely to blow up entirely of course. However, back to Smith.

Adam Smith pointed out, not in exactly these words but we can modernise his prose, put it in the demotic, that capitalists are greedy little so and sos. They’re always looking to make larger profits than they are currently. We can look around us and see that there’s an average rate of return to capital in the economy: we might adjust that for risk these days in the way that Smith didn’t. But his point was that there is this average and everyone’s always looking for ways to make more than this average. This is what drives people into looking for new businesses, new ways of doing business, to see if they offer super, or above this average level of, profits.

Of course this doesn’t stop there: some will find a method of making these higher profit levels. At which point others will note what is happening and start to move their own capital over into this new field. At which point we’ve several people competing for these super-profits and they get competed away. Thus, possibly with a bit of overshoot, that newly colonised business area reverts back to the average profit level of the entire economy.

We can see this in those new and small hedge funds. They come up with a new tactic, a new method of investing, perhaps they spot some correlation that no one else has as yet. When new and small they can make their profits out of what they’ve understood about the economy better than anyone else. But if they consistently make those extra profits then people are going to come looking at what they’re doing and start to copy them. And no inefficiency in the economy is large enough for everyone to exploit it at the same time. It’s the very success of the new techniques that attracts more capital and thus competes away those extra profits.

We can also say much the same about the hedge fund industry as a whole. Back a couple of decades there were a few hundred billions in the entire global industry. A decade and more before that only a few tens of billions. Those early funds really did have vast success: they were very definitely making super profits. Thus more capital flooded into the sector until there’s $2.7 trillion in it now. It might be premature to say that the industry is now entirely mature and creating only the average profit level of the entire economy (recall, we must adjust for risk to make this comparison) but it would certainly be true to say that it is maturing. The average return of the average fund is not notably above general investment returns elsewhere.

All of which is as Adam Smith would have predicted: the early success of the new method attracted ever more capital to the sector until those super profits are being competed away.

Tim Worstall, Contributor
Posted on 5/09/2014 @ 10:58AM
Article from http://www.forbes.com/

Friday, May 02, 2014

How Hedge Funds Are Pushing Companies To Leave America

Nathan Vardi, Forbes Staff
Posted on 5/01/2014 @ 12:00PM
Article from http://www.forbes.com/sites/nathanvardi/


Mallinckrodt is a pharmaceutical company specializing in pain treatment. Its name may sound foreign, but it traces back to the Mallinckrodt brothers, who founded the company in St. Louis in 1867. Most of the company’s sales take place in the U.S. and its main corporate office remains in Missouri. The one major foreign component of Mallinckrodt’s story is its legal domicile, which has been located for tax purposes in Ireland ever since it separated from Covidien and reemerged as an independent public company in 2013.

The biggest backers of Mallinckrodt are two of the nation’s most prominent hedge fund managers. The hedge fund of billionaire John Paulson, who became one of the nation’s richest men betting against subprime mortgages, is the biggest shareholder of Mallinckrodt with a 9.7% stake. Activist hedge fund manager Barry Rosenstein’s Jana Partners, which likes to impose its views on corporate management, is the third biggest shareholder in Mallinckrodt with a 5.69% stake.

In April, Mallinckrodt struck a deal to buy California-based Questcor Pharmaceuticals for $5.6 billion in cash and stock. Questcor is a controversial company that has dramatically increased the price of its key immune system drug. But Mallinckrodt’s Ireland domicile makes the deal compelling and paying taxes there will lower Questcor’s tax rate by 10%, according to Mallinckrodt.

Paulson is publicly pushing for the deal. Last week, Paulson’s hedge fund agreed to support the Mallinckrodt acquisition of Questcor with all the shares it owns in both companies in a deal that gives Paulson the ability to buy just under 20% of the company. Mallinckrodt’s Questcor acquisition comes on the heels of Mallinckrodt’s tax-driven $1.3 billion deal originally announced in February for San Diego-based Cadence Pharmaceuticals . “Mallinckrodt is an outstanding company with excellent management that is growing rapidly due to both internal and external factors,” Paulson & Co., said in a statement. “Competitive tax rates is just one of many factors that make the company an attractive investment.”

Prominent hedge funds are helping to fuel the wave of so-called inversion deals that are structured to lower tax rates by moving the domiciles of U.S. companies, particularly those operating in the pharmaceuticals sector, to foreign jurisdictions like Ireland. It’s pretty clear that Wall Street has cheered on the inversion trend, feasting on the investment banking fees generated by these deals, and that the markets even enjoy an increase in price of the stocks of both the seller and the buyer on the day the deals get announced. The business development offices of major U.S. pharmaceutical companies like Pfizer clearly know what they are doing. But hedge funds are playing a role in encouraging and even creating corporate deal machines that are engaging in tax-driven deals. For hedge funds, these deals are essentially a tax arbitrage trade. One place where these deals is less popular: Washington. The Obama Administration has said that “inversion transactions raise significant policy concerns because they facilitate the erosion of the U.S. tax base” and Pfizer’s recent $100 billion tax-lowering bid for AstraZeneca will only increase political attention.

But hedge funds are moving faster than Washington. Billionaire hedge fund manager William Ackman had never made a pharmaceutical investment before April. But last month his Pershing Square hedge fund made its biggest investment ever, taking a 10% stake in California-based Allergan. Ackman is making the $4 billion bet while working with Valeant, a company based in Canada whose senior executives work in New Jersey and has its tax-domicile in Barbados. Valeant has made a $45 billion bid that is driven by tax considerations to buy Allergan with Ackman.

Valeant itself is a hedge fund-created machine. ValueAct Capital Management, the activist hedge fund run by Jeffrey Ubben, has been a major shareholder for years and ValueAct’s Mason Morfit sits on the company’s board. Morfit even designed the highly-lucrative compensation package of Valeant CEO Michael Pearson, who has become a billionaire since he started running the company six years ago. When ValueAct got involved and Pearson started running the show, Valeant was based in California. Valeant then bought and folded the company into Canada’s Biovail to take advantage of Canada’s tax rules. Using Valeant’s lower tax structure, Pearson has done about 100 or so deals since 2008 and pushed Valeant’s stock up by some 800%.

Also in April, a group of high-profile hedge funds started to pressure Walgreen, America’s biggest pharmacy chain that is based in Illinois, to move to Europe for tax purposes. The Financial Times reported that activist hedge funds like Barry Rosenstein’s Jana Partners and Keith Meister’s Corvex Management, together with billionaire Dan Och’s Och-Ziff Capital Management hedge fund and Goldman Sachs, urged Walgreen’s senior management in a meeting in Paris to domicile its tax base in Europe as part of its $16 billion takeover of Alliance Boots, which is based in Switzerland.

Another major recent inversion story, Endo International, has been a den for so-called Tiger Cub hedge funds. John Griffin’s Blue Ridge Capital hedge fund owns 5% of the company. Other big Tiger Cub holders have been billionaire Stephen Mandel’s Lone Pine Capital and billionaire Andreas Halvorsen’s Viking Global Investors. A non-Tiger Cub owner of the stock is Jana Partners. The company was based in Pennsylvania, but moved its domicile to Ireland after agreeing in November to buy Canadian-based Paladin Labs for $1.6 billion. Halvorsen’s hedge fund sold its position in the company in the quarter when the deal was announced. There is no evidence Endo’s hedge fund investors did anything to support Endo’s decision to do an inversion deal, but they certainly benefited when the stock popped after the deal was announced.

Nathan Vardi, Forbes Staff
Posted on 5/01/2014 @ 12:00PM
Article from http://www.forbes.com/sites/nathanvardi/


Tuesday, April 22, 2014

Activist hedge funds target Europe amid increasing power

By Ashley Armstrong
6:00AM BST 22 Apr 2014
From http://www.telegraph.co.uk/finance/

The City will increasingly be targeted by activist hedge funds with 40pc of funds reporting they are looking at opportunities outside North America

Activist hedge funds have tripled the amount of money under management in the past five years and are aiming their cash piles at Europe, according to research compiled by FTI Consulting and Hedge Fund Research.

Such funds managed more than $93bn (£55bn) last year, almost triple that of five years ago and 42pc up from an estimated $65bn in 2012. The overall hedge fund industry is worth around $2.5  trillion.

Investors are pouring into activist funds, driven by higher returns of 16.6pc last year on investment which has far outpaced the average hedge fund return of 9.3pc.

As activism becomes a growing asset class for investors, proponents will have more power to increase their influence on M&A transactions and funds will be able to target even larger companies.

Out of the sample of economic activist funds engaged in more than 500 situations, 89pc believed there would be an increase in general activism, with involvement in M&A situations showing biggest increase this year.

According to the survey, 40pc of US investors are now looking at shifting their focus outside North America. Most recently, gaming analyst Jason Ader’s Spring Owl fund has gained a 6.1pc stake in bwin.party and has proposed four representatives onto the board. Edward Bramson’s Sherbourne Investments has taken a stake in Electra, following a passive involvement in 3i and a much more activist role in F&C Asset Management.

Transport company FirstGroup is also fighting pressure from US hedge fund Sandell Asset Management, and Elliott Investors has taken a stake in grocer Wm Morrison. Cevian Capital has also taken a stake in embattled security group G4S.

Cevian, one of Europe’s biggest activist investors, has said that it takes around three to five years to implement changes in larger companies.

In M&A, it is common for activists to take positions in target companies and push for an increase in the offer price – a practice that has been dubbed “bumpitrage”. However, the survey of leading economic activists by FTI Consulting in partnership with Activist Insight, has shown that 43pc of them are now willing to take positions in buyers and convince them not to do the deal.

Activists are also becoming more sophisticated in engaging with social media for maximum affect.

“When Carl Icahn took an activist stake in Apple, he announced it via Twitter,” Steven Balet, managing director and activism specialist in the Strategic Communications segment at FTI Consulting, said. “The impact was immediate and moved the markets – it was a lesson that everyone in the activist community noted and one that is likely to be emulated.”


By Ashley Armstrong
6:00AM BST 22 Apr 2014
From http://www.telegraph.co.uk/finance/